Biovica Q1 Update - Capitalised but the launch is still not in full swing
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2025-09-12 16:21:00
Biovica continues to increase 12m rolling IVD test sales in Q1 of SEK 0.93m (167% rolling 12m) and total net sales of SEK 2.6m after adding ROU & Pharma sales (test and services). Biovica is also progressing with a guaranteed rights issue at SEK 80m plus a SEK 42.2m Direct Share Issue (gross) and advancing the sales outlook based on Tempus AI in the Oncology segment, with a major partner in the IDN segment
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/